FIGURE 2 from LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency

LP-184 response is enhanced in HRD prostate cancer cell lines. Dose–response curves for 3-day treatment of PC3M cells with LP-184 in parental and ATM stable knockdown (A), and in parental and BRCA2 stable knockdown (B), in comparison with olaparib in parental and ATM stable knockdown (C), and in parental and BRCA2 stable knockdown (D). Data shown as mean ± SEM.